Your browser doesn't support javascript.
loading
Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy.
Karponi, Garyfalia; Psatha, Nikoletta; Lederer, Carsten Werner; Adair, Jennifer Eileen; Zervou, Fani; Zogas, Nikolaos; Kleanthous, Marina; Tsatalas, Constantinos; Anagnostopoulos, Achilles; Sadelain, Michel; Rivière, Isabelle; Stamatoyannopoulos, George; Yannaki, Evangelia.
Afiliação
  • Karponi G; Gene and Cell Therapy Center, Hematology Department-Bone Marrow Transplantation Unit, George Papanicolaou Hospital, Thessaloniki, Greece; School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece;
  • Psatha N; Gene and Cell Therapy Center, Hematology Department-Bone Marrow Transplantation Unit, George Papanicolaou Hospital, Thessaloniki, Greece;
  • Lederer CW; Molecular Genetics Thalassaemia Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus;
  • Adair JE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine and Markey Molecular Medicine Center, University of Washington, Seattle, WA;
  • Zervou F; Gene and Cell Therapy Center, Hematology Department-Bone Marrow Transplantation Unit, George Papanicolaou Hospital, Thessaloniki, Greece;
  • Zogas N; Gene and Cell Therapy Center, Hematology Department-Bone Marrow Transplantation Unit, George Papanicolaou Hospital, Thessaloniki, Greece;
  • Kleanthous M; Molecular Genetics Thalassaemia Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus;
  • Tsatalas C; School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece;
  • Anagnostopoulos A; Gene and Cell Therapy Center, Hematology Department-Bone Marrow Transplantation Unit, George Papanicolaou Hospital, Thessaloniki, Greece;
  • Sadelain M; Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center, New York, NY; and.
  • Rivière I; Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center, New York, NY; and Cell Therapy and Cell Engineering Facility, Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Stamatoyannopoulos G; Department of Medicine and Markey Molecular Medicine Center, University of Washington, Seattle, WA;
  • Yannaki E; Gene and Cell Therapy Center, Hematology Department-Bone Marrow Transplantation Unit, George Papanicolaou Hospital, Thessaloniki, Greece;
Blood ; 126(5): 616-9, 2015 Jul 30.
Article em En | MEDLINE | ID: mdl-26089395
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Genética / Fator Estimulador de Colônias de Granulócitos / Talassemia beta / Transplante de Células-Tronco Hematopoéticas / Mobilização de Células-Tronco Hematopoéticas Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Genética / Fator Estimulador de Colônias de Granulócitos / Talassemia beta / Transplante de Células-Tronco Hematopoéticas / Mobilização de Células-Tronco Hematopoéticas Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article